Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (301-310 of 333) with videos related to

Pageof 34
Sort By:
Journal of Clinical Epidemiology|March 24, 2024
Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, CanadaZoë R Greenwald, Dan Werb, Jordan J Feld, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosisLesley A Patmore, Lilian Y Liang, George Papatheodoridis, et al.
Gut|February 12, 2013
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis CYaron Rotman, Mazen Noureddin, Jordan J Feld, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|May 12, 2020
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label studyJordan J Feld, Marcelo Cypel, Deepali Kumar, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis BCalvin Q Pan, Samer Saadi, Marc G Ghany, et al.
Pageof 34

Showing results (301-310 of 333) with videos related to

Sort By:
Pageof 34
Journal of Clinical Epidemiology|March 24, 2024
Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, CanadaZoë R Greenwald, Dan Werb, Jordan J Feld, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosisLesley A Patmore, Lilian Y Liang, George Papatheodoridis, et al.
Gut|February 12, 2013
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis CYaron Rotman, Mazen Noureddin, Jordan J Feld, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|May 12, 2020
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label studyJordan J Feld, Marcelo Cypel, Deepali Kumar, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis BCalvin Q Pan, Samer Saadi, Marc G Ghany, et al.
Pageof 34